Ceftazidime/avibactam (Zavicefta®). HTA ID: 21003

Assessment Status Rapid Review complete
HTA ID 21003
Drug Ceftazidime/avibactam
Brand Zavicefta®
Indication For paediatric patients aged three months and older for the treatment of: Complicated intra-abdominal infection (cIAI); Complicated urinary tract infection (cUTI), including pyelonephritis; Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); Infections due to aerobic Gram-negative organisms in patients with limited treatment options
Assessment Process
Rapid review commissioned 09/02/2021
Rapid review completed 04/03/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that of ceftazidime-Avibactam (Zavicefta®) not be considered for reimbursement at the submitted price*.

 *This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.